Addressing Aβ interactions with drugs that are substrates of P-gp may afford the potential to reduce Aβ accumulation and thereby reduce the incidence of AD as the impaired function of P-gp in AD patients increases Aβ accumulation, contributing to the progression of neurodegenerative processes. The gene discussed is PGP; the disease is Alzheimer disease.